摘要
Abstract
OBJECTIVE: To evaluate efficacy and safety of ambroxol in the prevention of neonatal respiratory distress syndrome (NRDS). METHODS: Random controlled trails (RCT) of ambroxol vs. Placebo for NRDS were retrieved from Cochrane library, PubMed, EMBase, ISI, CBMdisc, CNKI, VTP, Wangfang database. Quality evaluation and Meta-analysis of included studies were conducted. RESULTS: 13 RCTs involving 1 377 patients of ambroxol vs. Placebo in the prevention of NRDS were included. The incidence of NRDS in 2 groups had statistical significance [RR=0.44, 95%CI(0.32,0.61), P<0.000 01]; the mortality after NRDS in 2 groups had statistical significance [RR=0.40,95%CI(0.17,0.94),P=0.03]; the incidence of complication had statistical significance [RR=0.10, 95% CI (0.05,0.19), P<0.000 01]. There was no statistical significance in the difference of ADR. CONCLUSION: According to the evidence currently, ambroxol in the prevention of NRDS could decrease the incidence of NRDS and the mortality after NRDS, reduce the incidence of complication.关键词
氨溴索/新生儿呼吸窘迫综合征/有效性/安全性/Meta分析Key words
Ambroxol/ Neonatal respiratory distress syndrome/ Efficacy/ Safety/ Meta-analysis分类
医药卫生
